Inactief instrument

Andere talen Alder BioPharmaceuticals, Inc.

Aandelen

US0143391052

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Alder BioPharmaceuticals, Inc. Announces Board Changes	22-10-19
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Biotechnology Select Industry Index	22-10-19
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Global BMI Index	22-10-19
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P TMI Index	22-10-19
H. Lundbeck A/S completed the acquisition of Alder BioPharmaceuticals, Inc..	22-10-19
Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC	11-10-19
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine	10-10-19
Alder BioPharmaceuticals, Inc. Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine	10-10-19
WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc.	18-09-19
Dow Jones Industrial Average : Les valeurs à suivre à Wall Street	16-09-19
USA-Les valeurs à suivre à Wall Street	16-09-19
H Lundbeck : Lundbeck buys Alder in $2 billion migraine treatment move	16-09-19
Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash	16-09-19
H. Lundbeck A/S signed a Letter of Intent to acquire Alder BioPharmaceuticals, Inc. for $1.5 billion.	16-09-19
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society	05-09-19
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	30-08-19
Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences	28-08-19
Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results	06-08-19
Alder Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	06-08-19
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02-08-19

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Alder BioPharmaceuticals, Inc.

Aandelen

US0143391052

Andere talen

Filters